Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data

LP Petalidis, A Oulas, M Backlund, MT Wayland… - Molecular cancer …, 2008 - AACR
LP Petalidis, A Oulas, M Backlund, MT Wayland, L Liu, K Plant, L Happerfield, TC Freeman
Molecular cancer therapeutics, 2008AACR
Histopathologic grading of astrocytic tumors based on current WHO criteria offers a valuable
but simplified representation of oncologic reality and is often insufficient to predict clinical
outcome. In this study, we report a new astrocytic tumor microarray gene expression data set
(n= 65). We have used a simple artificial neural network algorithm to address grading of
human astrocytic tumors, derive specific transcriptional signatures from histopathologic
subtypes of astrocytic tumors, and asses whether these molecular signatures define survival …
Abstract
Histopathologic grading of astrocytic tumors based on current WHO criteria offers a valuable but simplified representation of oncologic reality and is often insufficient to predict clinical outcome. In this study, we report a new astrocytic tumor microarray gene expression data set (n = 65). We have used a simple artificial neural network algorithm to address grading of human astrocytic tumors, derive specific transcriptional signatures from histopathologic subtypes of astrocytic tumors, and asses whether these molecular signatures define survival prognostic subclasses. Fifty-nine classifier genes were identified and found to fall within three distinct functional classes, that is, angiogenesis, cell differentiation, and lower-grade astrocytic tumor discrimination. These gene classes were found to characterize three molecular tumor subtypes denoted ANGIO, INTER, and LOWER. Grading of samples using these subtypes agreed with prior histopathologic grading for both our data set (96.15%) and an independent data set. Six tumors were particularly challenging to diagnose histopathologically. We present an artificial neural network grading for these samples and offer an evidence-based interpretation of grading results using clinical metadata to substantiate findings. The prognostic value of the three identified tumor subtypes was found to outperform histopathologic grading as well as tumor subtypes reported in other studies, indicating a high survival prognostic potential for the 59 gene classifiers. Finally, 11 gene classifiers that differentiate between primary and secondary glioblastomas were also identified. [Mol Cancer Ther 2008;7(5):1013–24]
AACR